Richard Gorlick

29PUBLICATIONS
190CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersData qualitySolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|May 14, 2026
PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

|Apr 06, 2026
Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.

Edward Favours, Haiying Tang, Peyton Wong

|Jan 10, 2026
Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models.

Yifei Wang, Zhongting Zhang, Caterina Longo

|Oct 29, 2025
A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology Group.

Katherine A Janeway, Alexander J Chou, Allen Buxton

|Oct 06, 2025
Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas.

Jiemiao Hu, Harjeet Singh, Yining Jin

|Sep 08, 2025
Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma.

Michelle Choe, Danielle Kirkey, Isabel Lira

Pageof 5

Frequent Collaborators

9 joint publications

Jonathan Gill

8 joint publications

Katherine Janeway

7 joint publications

Damon Reed

6 joint publications

Malcolm A Smith